Literature DB >> 31165904

Matrix metalloproteinases and ADAMs in stroke.

Joan Montaner1, Laura Ramiro2, Alba Simats2, Mar Hernández-Guillamon2, Pilar Delgado2, Alejandro Bustamante2, Anna Rosell2.   

Abstract

Stroke is a leading cause of death and disability worldwide. However, after years of in-depth research, the pathophysiology of stroke is still not fully understood. Increasing evidence shows that matrix metalloproteinases (MMPs) and "a disintegrin and metalloproteinase" (ADAMs) participate in the neuro-inflammatory cascade that is triggered during stroke but also in recovery phases of the disease. This review covers the involvement of these proteins in brain injury following cerebral ischemia which has been widely studied in recent years, with efforts to modulate this group of proteins in neuroprotective therapies, together with their implication in neurorepair mechanisms. Moreover, the review also discusses the role of these proteins in specific forms of neurovascular disease, such as small vessel diseases and intracerebral hemorrhage. Finally, the potential use of MMPs and ADAMs as guiding biomarkers of brain injury and repair for decision-making in cases of stroke is also discussed.

Entities:  

Keywords:  ADAM; Biomarker; MMP; Neuroprotection; Neurorepair; Stroke

Mesh:

Substances:

Year:  2019        PMID: 31165904     DOI: 10.1007/s00018-019-03175-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

Review 1.  Metalloproteinases in nervous system function and pathology: introduction.

Authors:  Santiago Rivera
Journal:  Cell Mol Life Sci       Date:  2019-06-07       Impact factor: 9.261

Review 2.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 3.  Matrix Metalloproteinases in Acute Intracerebral Hemorrhage.

Authors:  Simona Lattanzi; Mario Di Napoli; Silvia Ricci; Afshin A Divani
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

Review 4.  Neuroinflammation and fibrosis in stroke: The good, the bad and the ugly.

Authors:  Narayanappa Amruta; Abir A Rahman; Emmanuel Pinteaux; Gregory Bix
Journal:  J Neuroimmunol       Date:  2020-07-09       Impact factor: 3.478

Review 5.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Authors:  Gregg B Fields
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

Review 6.  Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP.

Authors:  Laura García-González; Dominika Pilat; Kévin Baranger; Santiago Rivera
Journal:  Front Aging Neurosci       Date:  2019-09-24       Impact factor: 5.750

Review 7.  Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.

Authors:  Ricardo O S Soares; Daniele M Losada; Maria C Jordani; Paulo Évora; Orlando Castro-E-Silva
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

8.  SerpinA3N deficiency deteriorates impairments of learning and memory in mice following hippocampal stab injury.

Authors:  Zhi-Meng Wang; Cong Liu; Ying-Ying Wang; Yu-Sen Deng; Xuan-Cheng He; Hong-Zhen Du; Chang-Mei Liu; Zhao-Qian Teng
Journal:  Cell Death Discov       Date:  2020-09-18

9.  Association of Matrix Metalloproteinase 9 and Cellular Fibronectin and Outcome in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Lu Wang; Linghui Deng; Ruozhen Yuan; Junfeng Liu; Yuxiao Li; Ming Liu
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

10.  New candidate blood biomarkers potentially associated with white matter hyperintensities progression.

Authors:  Joan Jiménez-Balado; Jesús Pizarro; Iolanda Riba-Llena; Anna Penalba; Júlia Faura; Elena Palà; Joan Montaner; Mar Hernández-Guillamon; Pilar Delgado
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.